Bernstein analyst William Pickering maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) yesterday and set a price ...
Equities researchers at Zacks Research decreased their Q3 2026 earnings per share (EPS) estimates for shares of Vertex ...
UnitedHealth includes Vertex’s non-opioid painkiller in coverage, but at a higher cost - Bloomberg
Investing.com -- Vertex Pharmaceuticals Inc (NASDAQ: VRTX ).’s newly approved non-opioid pain medication, Journavx, has been included in UnitedHealth Group Inc (NYSE: UNH ).’s coverage, according to ...
Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...
With a market cap of $124.9 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a global biotechnology company. The Boston ...
Shares of Vertex Pharmaceuticals Inc. VRTX advanced 1.11% to $491.64 Wednesday, on what proved to be an all-around favorable ...
TD Cowen analyst Phil Nadeau maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target of ...
We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...
EDIT stock is down following the announcement of dismal fourth-quarter 2024 results as both earnings and revenues miss estimates.
2d
Vertex Pharmaceuticals Incorporated ( NASDAQ: VRTX) TD Cowen 45th Annual Health Care Conference Transcript March 3, 2025 3:10 PM ET David Altshuler - Executive Vice President, Global Research and CSO ...
AbbVie, Thermo Fisher Scientific, Danaher, Vertex Pharmaceuticals, and Illumina are the five Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech stocks represent ...
The pharma industry is delivering game-changing therapies with favorable regulatory support. Amid this backdrop, investors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback